10000 documents

University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Raymond Scott McClelland · UNIVERSITY OF WASHINGTON · 2021 · $1,259,301 — The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus disease of 2019 (COVID-19) pandemic, has infected over 126 million people worldwide and resulted in over 2.7 million deaths, including > 548,000 in the United States (March 27, 2021, WHO; www.who.int…

Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site: DMID 21-0012 Mix and Match

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Karen L. Kotloff · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $1,121,472 — Summary/Abstract The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus disease of 2019 (COVID-19) which was designated as a pandemic respiratory illness (WHO - 2020), has infected over 172 million people worldwide and resulted in over 3.7 million deaths…

Molecular Approaches To Antiviral and Vaccine Development For Viral Hepatitis and Other Viral Diseases

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $1,696,123 — Therapy for hepatitis C virus (HCV) infection has advanced rapidly with the recent approval of several direct-acting antivirals. However, most of the DAAs in clinical use or clinical trials target the same stage of HCV replication cycle and are associated with rapid emergence of drug-resistant viral…

Project 4: Computational panbetaCoV immunogen design

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Rory Henderson · DUKE UNIVERSITY · 2021 · $1,863,181 — Abstract - Project 4 SARS-CoV-2, a member of the genus Betacoronavirus (betaCoV), is the third major zoonotic outbreak of a highly pathogenic betaCoV in the last two decades. We propose to design vaccines to contribute to the global effort to counter the COVID-19 pandemic as swiftly as possible, and…

Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $35,539 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…

Production and purification of biological compounds

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Joseph Shiloach · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $531,271 — Summary: An essential part of the Lab activities is production of unique biologicals that are not available from commercial sources at a suitable quality, for basic and clinical research. During the last year the Lab performed several processes, which include propagation of bacteria, and mammalian c…

Comparative Analysis Of Completely Sequenced Genomes

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Eugene V Koonin · NATIONAL LIBRARY OF MEDICINE · 2021 · $3,221,620 — The rapidly growing database of completely and nearly completely sequenced genomes of bacteria, archaea, eukaryotes and viruses (millions of genomes already available and many more in progress) creates both extensive new opportunities and major new challenges for genome research. During the year in …

Recombinant Engineering of SARS-CoV-2 Spike and N proteins

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

David Margulies · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $27,720 — We have successfully engineering and produced a number of SARS-CoV-2 proteins, subunits, and single domain antibodies directed against the RBD. These purified proteins have provided the materials for obtaining high resolution crystal structures of four of these sybodies in complex with the Spike rec…

Novel SARS-CoV-2 vaccine candidates: Live, recombinant Leishmania

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

David Sacks · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $18,682 — In order to overexpress SARS CoV-2 spike protein (S) in Leishmania, the full length S gene sequence was amplified by PCR from plasmid pCAGGS containing the Wuhan-Hu-1 spike and inserted into plasmid pSSU-NEO using a Gibson Assembly reaction, with the addition of an N-terminal myc tag and a C-termi…

Determining factors of transmission and evolution of SARS-CoV-2 in populations at risk

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Elodie Ghedin · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $137,932 — The major aspects of this project involve characterizing SARS-CoV-2 genetic diversity and microbial communities in the respiratory tract during infection. This involves analyzing samples from COVI19 positive subjects, and from model animal infections. Whole genome sequencing of SARS-CoV-2 has becom…

Viral Vector Core

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

JERREL L YAKEL · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2021 · $1,516,365 — The Viral Vector Core facility currently offers support for production, purification, titering, and validation of twelve types of viruses: Adenovirus, Adenoassociated virus (AAV), coronaviruses (229E, OC43, NL63, and MHV), Herpes Simplex Virus (HSV), Influenza A, lentiviruses including human immunod…

COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Donald Lo · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2021 · $1,352,770 — We have worked in collaboration with experts in and outside of NIH on the development of 8 assays for use in repurposing screens of approved drug collections to identify compounds active against SARS-CoV-2. The compounds identified from such screens have potential for clinical trials as single agent…

Mass Spectrometry Characterization

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Leesa Deterding · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2021 · $574,792 — Mass spectrometry has been used to determine the extent of modification and the specific sites of modification on biomolecules. MS-based approaches have many advantages, including generally rapid analyses without radiolabeling. The MS analysis of a variety of proteins has been investigated using mas…

Structural study of the HIV1 gp41 coat protein

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Adriaan Bax · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $658,712 — The envelope glycoprotein gp41 mediates the process of membrane fusion that enables entry of the HIV-1 virus into the host cell. On the surface of the virus, gp41 is part of the large homotrimeric glycoprotein gp160, and previous work by us has shown that, in contrast with literature reports, the tr…

SARS-CoV-2 Immunology and Therapeutics

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

KIM HASENKRUG · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $29,973 — We have completed the testing of SARS-CoV-2-infected rhesus macaques that were depleted of CD4+ or CD8+ T cells or dually depleted of both subsets and the results have been published (Hasenkrug et al. 2021). 6 macaques in each of 4 groups including a control non-depleted group have been analyzed. …

Structural and chemical biology of membrane proteins

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Anirban Banerjee · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2021 · $2,347,622 — 1) Structure and function of eukaryotic integral membrane enzymes that catalyze protein lipidation - A. Structural and chemical biology of zDHHC palmitoylacyltransferases - Thousands of cellular proteins are modified by posttranslational S-acylation of cysteines, commonly known as protein palmitoy…

Human Immune Responses to Tumor Antigens for Cancer Immunotherapy

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

JEFFREY SCHLOM · DIVISION OF BASIC SCIENCES - NCI · 2021 · $1,593,930 — INTERROGATION OF THE CELLULAR IMMUNOME OF CANCER PATIENTS WITH REGARD TO THE COVID-19 PANDEMIC. While vaccines directed against the SARS-CoV-2 spike protein will have varying degrees of effectiveness in preventing SARS-CoV-2 infections, the severity of infection will be determined by multiple host f…

Studies of the SARS-CoV-2 Spike Protein

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

JAY A BERZOFSKY · DIVISION OF BASIC SCIENCES - NCI · 2021 · $1,303,369 — Due to the recent initiation of this project (April 2020) during the partial lab closure during the pandemic, progress on the objectives listed above has been limited, although 2 papers have been published already. In vitro studies in macaque bronchioalveolar lavage cells: So far, we have seen some …

COVID-19 research efforts

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Thomas Waldmann · DIVISION OF BASIC SCIENCES - NCI · 2021 · $450,222 — Dr. Liyanage P. Perera, a member of our group, is an expert in the introduction of IL-15 into vaccines to augment their function. He is working on 2 candidate vaccines for COVID-19, a full-length spike S protein, as well as a truncated subdomain of it that carries the receptor-binding domain of a Na…

Deciphering the Double-Edged Role of IFITM3 during SARS-CoV-2 Infection

NIH Pandemic-Era Grants · Pandemic Era Grants / 2021

Alex Compton · DIVISION OF BASIC SCIENCES - NCI · 2021 · $89,017 — Scarlett Shi, a Research Fellow in the lab, is leading this project. We have successfully produced HIV-based pseudovirus bearing the spike protein of SARS-CoV-1 and SARS-CoV-2 and produced cell lines that are permissive to these pseudoviruses. We have developed a protocol for transiently transfectin…